Laurion Capital Management’s Anebulo Pharmaceuticals ANEB Stock Holding History

Laurion Capital Management’s Portfolio ANEB Stock Details ANEB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-219,583	Closed	-$1.48M	–	474
2022 Q1	$1.48M	Sell	219,583 -5,417	-2%	-$37.1K	0.02%	229
2021 Q4	$1.4M	Hold	225,000	–	–	0.01%	317
2021 Q3	$1.51M	Hold	225,000	–	–	0.01%	465
2021 Q2	$1.55M	Buy	+225,000	New	+$1.67M	0.01%	389

Other funds holding ANEB

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Laurion Capital Management's ANEB Position: Q2 2022 in Review

Laurion Capital Management sold out of Anebulo Pharmaceuticals (ANEB) in Q2 2022, closing a stake of 219,583 shares — an estimated $1.48M sold.

Laurion Capital Management first reported a position in ANEB in Q2 2021 and held it in 4 quarters. The position peaked at $1.55M in Q2 2021. 9 funds tracked by Wall St. Rank hold ANEB as of Q2 2022.

Laurion Capital Management reported no remaining Anebulo Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Laurion Capital Management sold 219,583 Anebulo Pharmaceuticals shares in Q2 2022, an estimated $1.48M.
Laurion Capital Management first reported a position in Anebulo Pharmaceuticals in Q2 2021 and held it in 4 quarters.
Laurion Capital Management's Anebulo Pharmaceuticals position peaked at $1.55M in Q2 2021.
9 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q2 2022.

Based on Laurion Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.